Prognostic factors for patients treated with abiraterone

Prognostic factors for patients treated with abiraterone

Aim: To evaluate prostate-specific antigen response (PSAr) defined as a ≥50% decrease in PSA concentration from the pretreatment value, as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). Methods: Retrospective evalua...

Full description

Saved in:
Bibliographic Details
Main Authors: Cecília M Alvim, André Mansinho, Rita S Paiva, Raquel Brás, Patrícia M Semedo, Soraia Lobo-Martins, Carolina B da Ponte, Daniela Macedo, Leonor Ribeiro, José P dos Reis, Isabel Fernandes, Luís Costa
Format: Article
Language:English
Published: Taylor & Francis Group 2020-02-01
Series:Future Science OA
Subjects:
abiraterone acetate
metastatic castration-resistant prostate cancer
prostate-specific antigen response
Online Access:https://www.future-science.com/doi/10.2144/fsoa-2019-0079
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim: To evaluate prostate-specific antigen response (PSAr) defined as a ≥50% decrease in PSA concentration from the pretreatment value, as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). Methods: Retrospective evaluation of patients with mCRPC treated with AA. Results: 124 patients were identified. Median overall survival and progression-free survival for patients achieving PSAr versus patients without PSAr were 29.3 versus 9.7 months and 17.0 versus 5.2 months, respectively. Multivariate analysis confirmed that PSAr correlated with better overall survival (hazard ratio: 0.19; 95% CI: 0.10−0.38; p < 0.001) and progression-free survival (hazard ratio: 0.24; 95% CI: 0.14−0.41; p < 0.001). Conclusion: PSAr can be utilized as prognostic and predictive factors in mCRPC patients treated with AA.
ISSN:2056-5623

Similar Items